United States · Bill · HR
H.R. 4117 (115th)
Competitive DRUGS Act of 2017
Introduced
25 October 2017
Last action
—
Status
Referred to the Subcommittee on Digital Commerce and Consumer Protection.
Sponsors
—
Subjects
Discovery layer
Source updated
11 August 2025
Summary
Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017 This bill establishes a series of requirements and prohibitions regarding certain patent infringement agreements between brand name and generic drug manufacturers in which the generic drug manufacturer agrees to delay the availability of applicable generic drugs. Among other things, the bill specifies that such agreements constitute an unfair method of competition and are subject to specified civil penalties.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 25 October 2017
Introduced in House (PDF)
Introduced in House · EN · 25 October 2017
Introduced in House
summary · EN · 25 October 2017
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/115th-congress/house-bill/4117
- Open data entity: https://api.congress.gov/v3/bill/115/hr/4117